[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR047722A1 - Sistema de tranferencia de liberacion controlada para aplicaciones nasales - Google Patents

Sistema de tranferencia de liberacion controlada para aplicaciones nasales

Info

Publication number
AR047722A1
AR047722A1 ARP040103611A ARP040103611A AR047722A1 AR 047722 A1 AR047722 A1 AR 047722A1 AR P040103611 A ARP040103611 A AR P040103611A AR P040103611 A ARP040103611 A AR P040103611A AR 047722 A1 AR047722 A1 AR 047722A1
Authority
AR
Argentina
Prior art keywords
formulation
controlled release
formulation according
mixture
nasal
Prior art date
Application number
ARP040103611A
Other languages
English (en)
Inventor
Claudia Mattern
Original Assignee
Mattern Udo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mattern Udo filed Critical Mattern Udo
Publication of AR047722A1 publication Critical patent/AR047722A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Preparacion administrable por vía nasal para la liberacion controlada de las hormonas sexuales a la circulacion sistémica, en particular a una formulacion la cual permite que su ingrediente activo sea absorbido de forma sostenida para proveer mejor biodisponibilidad en dosis muy bajas y de mayor duracion de accion. Reivindicacion 1: Una formulacion para la aplicacion nasal que comprende a) al menos una droga de hormona sexual; b) al menos un portador lipofílico o parcialmente lipofílico; y c) un compuesto o una mezcla de los compuestos que presenta una actividad que disminuye la tension superficial, en una cantidad efectiva para la generacion in situ de una emulsion una vez que la formulacion toma contacto con el agua. Reivindicacion 4: La formulacion de acuerdo con la reivindicacion 3, en donde dicho aceite es un aceite de ricino. Reivindicacion 7: La formulacion de acuerdo con la reivindicacion 6, en donde el componente (c) comprende macrogolglicérido oleico o una mezcla de macrogolglicéridos oleico. Reivindicacion 13: La formulacion de acuerdo con una cualquiera de las reivindicaciones precedentes, en donde la droga de la hormona sexual es testosterona.
ARP040103611A 2003-11-11 2004-10-05 Sistema de tranferencia de liberacion controlada para aplicaciones nasales AR047722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03025769A EP1530965B1 (en) 2003-11-11 2003-11-11 Controlled release delivery system of sexual hormones for nasal application

Publications (1)

Publication Number Publication Date
AR047722A1 true AR047722A1 (es) 2006-02-15

Family

ID=34429314

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103611A AR047722A1 (es) 2003-11-11 2004-10-05 Sistema de tranferencia de liberacion controlada para aplicaciones nasales

Country Status (23)

Country Link
US (6) US20050100564A1 (es)
EP (1) EP1530965B1 (es)
JP (1) JP4616270B2 (es)
KR (1) KR100861443B1 (es)
AR (1) AR047722A1 (es)
AT (1) ATE319426T1 (es)
AU (1) AU2004286781B2 (es)
BR (1) BRPI0416370B8 (es)
CA (1) CA2541498C (es)
DE (1) DE60303854T2 (es)
DK (1) DK1530965T3 (es)
ES (1) ES2258694T3 (es)
HR (1) HRP20060147B1 (es)
MY (1) MY131483A (es)
NO (1) NO338665B1 (es)
PL (1) PL219338B1 (es)
PT (1) PT1530965E (es)
RU (1) RU2331423C2 (es)
SA (1) SA04250363B1 (es)
SI (1) SI1530965T1 (es)
TW (1) TWI350176B (es)
WO (1) WO2005044273A1 (es)
ZA (1) ZA200603115B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195895T1 (de) 1996-10-01 2000-09-15 Hubert Francois Verschleissfester verbundkörper
KR100860249B1 (ko) 2001-12-04 2008-09-25 마고또 앵떼르나씨오날 에스.에이. 개선된 내마모성을 갖는 주조 부품 및 그 제조 방법
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
PT1750766E (pt) 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
RU2480208C2 (ru) * 2006-10-04 2013-04-27 М Унд П Патент Акциенгезелльшафт Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров
US8147980B2 (en) 2006-11-01 2012-04-03 Aia Engineering, Ltd. Wear-resistant metal matrix ceramic composite parts and methods of manufacturing thereof
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
GB2482868A (en) 2010-08-16 2012-02-22 Franciscus Wilhelmus Henricus Maria Merkus A testosterone liquid spray formulation for oromucosal administration
AR086400A1 (es) * 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
CA2835911C (en) * 2011-05-13 2022-08-30 Trimel Biopharma Srl Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040922A1 (en) * 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) * 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
KR20230041081A (ko) * 2011-05-15 2023-03-23 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
EA039080B1 (ru) * 2011-05-16 2021-12-01 Эйсерус Биофарма Инк. Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
WO2013169067A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 류마티즘 관절염 예방 또는 치료 조성물
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
WO2014083432A2 (en) * 2012-11-14 2014-06-05 Trimel Biopharma Srl Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
CN105263508B (zh) 2013-04-19 2019-10-25 珍白斯凯尔有限公司 治疗和预防缺血性损伤的组合物
CA2912557A1 (en) 2013-06-07 2014-12-11 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
WO2014204281A1 (ko) * 2013-06-21 2014-12-24 주식회사 카엘젬백스 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
EP3061459B1 (en) 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
KR102694658B1 (ko) 2013-11-22 2024-08-14 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
KR102232320B1 (ko) 2014-04-30 2021-03-26 주식회사 젬백스앤카엘 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
ES2877107T3 (es) 2014-08-28 2021-11-16 Univ Texas Formulaciones de testosterona y procedimientos de tratamiento con ellas
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
WO2016137162A1 (ko) 2015-02-27 2016-09-01 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
ES2886946T3 (es) 2015-07-02 2021-12-21 Gemvax & Kael Co Ltd Péptido con efecto antiviral y composición que lo contiene
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
CN109069518B (zh) * 2016-03-02 2022-10-11 得克萨斯州大学系统董事会 睾酮制剂以及用其治疗的方法
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180123512A (ko) 2016-04-07 2018-11-16 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
MX2018014906A (es) 2016-06-03 2019-08-21 M et P Pharma AG Composiciones farmaceuticas nasales con un excipiente poroso.
WO2018134783A1 (en) 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
CA3051725A1 (en) 2017-02-02 2018-08-09 Otolanum Ag Intranasal composition comprising betahistine
CA3083757A1 (en) * 2017-11-27 2019-05-31 Aska Pharmaceutical Co., Ltd. Powder preparation for nasal administration
WO2019138356A1 (en) 2018-01-11 2019-07-18 M et P Pharma AG Treatment of demyelinating diseases
CA3066284A1 (en) 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
EP3781129A1 (en) 2018-04-17 2021-02-24 M Et P Pharma AG Compositions and methods for intranasal delivery of pregnenolone
BR112021007877A2 (pt) * 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
KR20210131305A (ko) * 2018-12-14 2021-11-02 아세러스 바이오파마 인크. 테스토스테론의 활성 에스테르 유도체, 조성물 및 그의 용도
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE943792C (de) * 1949-02-18 1956-06-01 Organon Nv Verfahren zur Herstellung von injizierbaren Hormonpraeparaten
GB1032874A (en) 1964-02-13 1966-06-15 Du Pont Stabilized polyoxymethylenes
NL7506407A (nl) * 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
NL7510104A (nl) * 1975-08-27 1977-03-01 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
DE2548413A1 (de) * 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US5049387A (en) * 1987-03-09 1991-09-17 Alza Corporation Inducing skin tolerance to a sensitizing drug
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
JP2543708B2 (ja) * 1987-07-13 1996-10-16 旭化成工業株式会社 難溶性薬物を封入したエマルジョン製剤の製造方法
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5221698A (en) 1991-06-27 1993-06-22 The Regents Of The University Of Michigan Bioactive composition
US5756071A (en) * 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
WO1995020945A1 (en) 1994-02-04 1995-08-10 Scotia Lipidteknik Ab Lipophilic carrier preparations
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US5897894A (en) * 1997-12-29 1999-04-27 General Mills, Inc. Microwave popcorn with coarse salt crystals and method of preparation
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
GB9828861D0 (en) 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DK1189620T3 (da) * 1999-04-01 2004-08-16 Akzo Nobel Nv Formulering indeholdende testosteronundecanoat og amerikansk olie
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
CA2376797C (en) 1999-06-11 2011-03-22 Watson Pharmaceuticals, Inc. Administration of non oral androgenic steroids to women
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU7984200A (en) 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
CA2325106A1 (en) 1999-12-06 2001-06-06 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
JP2005504721A (ja) * 2001-03-06 2005-02-17 セレジィ ファーマシューティカルス， インコーポレイテッド 尿生殖障害の処置のための化合物および方法
US6833478B2 (en) 2001-07-13 2004-12-21 Sri International N,N-dinitramide salts as solubilizing agents for biologically active agents
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EA007431B1 (ru) 2002-03-15 2006-10-27 Юнимед Фармасьютикалз, Инк. Андрогенная фармацевтическая композиция и способ для лечения депрессии
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US6958142B2 (en) 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US7029657B2 (en) 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
CA2550811C (en) 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
RU2480208C2 (ru) 2006-10-04 2013-04-27 М Унд П Патент Акциенгезелльшафт Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров

Also Published As

Publication number Publication date
CA2541498A1 (en) 2005-05-19
US20120083480A1 (en) 2012-04-05
US20120009250A1 (en) 2012-01-12
MY131483A (en) 2007-08-30
DE60303854T2 (de) 2006-08-10
SI1530965T1 (sl) 2006-06-30
ZA200603115B (en) 2007-09-26
JP4616270B2 (ja) 2011-01-19
KR20060109903A (ko) 2006-10-23
RU2006120468A (ru) 2007-12-27
EP1530965B1 (en) 2006-03-08
HRP20060147A2 (en) 2006-11-30
PL379867A1 (pl) 2006-11-27
WO2005044273A1 (en) 2005-05-19
BRPI0416370B1 (pt) 2018-09-18
DE60303854D1 (de) 2006-05-04
EP1530965A1 (en) 2005-05-18
US20070149454A1 (en) 2007-06-28
US8784882B2 (en) 2014-07-22
HRP20060147B1 (hr) 2014-02-14
US8877230B2 (en) 2014-11-04
TWI350176B (en) 2011-10-11
JP2007530446A (ja) 2007-11-01
SA04250363B1 (ar) 2013-03-13
ES2258694T3 (es) 2006-09-01
RU2331423C2 (ru) 2008-08-20
PL219338B1 (pl) 2015-04-30
DK1530965T3 (da) 2006-07-17
NO338665B1 (no) 2016-09-26
PT1530965E (pt) 2006-05-31
BRPI0416370B8 (pt) 2021-05-25
KR100861443B1 (ko) 2008-10-02
CA2541498C (en) 2009-05-26
ATE319426T1 (de) 2006-03-15
AU2004286781B2 (en) 2010-06-03
BRPI0416370A (pt) 2007-05-22
US8574622B2 (en) 2013-11-05
US20050100564A1 (en) 2005-05-12
US20120058176A1 (en) 2012-03-08
NO20062619L (no) 2006-06-07
TW200515918A (en) 2005-05-16
US20100311707A1 (en) 2010-12-09
WO2005044273A8 (en) 2006-08-31
AU2004286781A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
AR047722A1 (es) Sistema de tranferencia de liberacion controlada para aplicaciones nasales
ES2581574T3 (es) Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
AR062059A1 (es) Espuma farmaceutica con acido graso
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
AR063446A1 (es) Sistema de administracion para el tratamiento remoto de un animal
CO6361898A2 (es) Emulsiones de liberacion modificadas para aplicacion en la piel o en la mucosa vaginal
AR075284A1 (es) Formulaciones fitosanitarias liquidas acuosas
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
PE20081297A1 (es) Forma de dosificacion transdermica resistente a la manipulacion
AR052616A1 (es) Dispositivo
BRPI0717509B8 (pt) sistema de liberação controlada para aplicação nasal de neurotransmissores
AR055363A1 (es) Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion
DK1333880T3 (da) Indretninger med coatede mikrofremspring til medikamentafgivelse gennem huden
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
PE20030519A1 (es) Forma de dosificacion, dispositivo y metodos de tratamiento
AR029005A1 (es) FORMULACION LíQUIDA ESTABLE SIN AGUA O CASI SIN AGUA DE BENCIMIDAZOLES SUSTITUIDOS, PROCESO PARA SU PREPARACIoN, USO DE ESTA FORMULACIoN, Y USO DE POLIETILENGLICOL Y UNA SAL DE SODIO O POTASIO DE UN INHIBIDOR DE H+, K+-ATP ASA
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
UY31059A1 (es) Formulaciones de aminoacido n-halogenado
CL2007002363A1 (es) Procedo para retrasar o prevenir la cristalizacion de un material que comprende crear gotitas encapsuladas de una solucion de un material activo que es sustancialmente insoluble en condiciones acuosas, donde el agente encapsulante es una pelicula for
AR052615A1 (es) Dispositivo
GT200500349A (es) Formulaciones de benzoxazoles substituidos
PE20050443A1 (es) Formulaciones farmaceuticas transdermicas
CL2004000767A1 (es) Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos.
AR066076A1 (es) Procedimiento para dosificar sistemas de liberacion de farmacos auto-emulsionantes

Legal Events

Date Code Title Description
FC Refusal